2022
DOI: 10.1590/1516-3180.2021.0098.r1.08062021
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as coronavirus disease-19 , is a new pandemic that appeared in the city of Wuhan, China, in December 2019. 1,2 Over the past four months, COVID-19 has become a worldwide pandemic, such that 32,150,495 cases and 982,680 deaths globally have been reported. In Spain, 682,267 cases and 45,252 deaths were reported up to September 24, 2020. Although the majority of COVID-19 cases have resolved spontaneously, some have developed… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
10
0
1

Year Published

2022
2022
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 34 publications
0
10
0
1
Order By: Relevance
“…Eight of the 11 RCTs compared therapeutic versus prophylactic doses of anticoagulants, and three trials compared moderate therapeutic versus prophylactic doses of anticoagulants. Seven of the 17 OBs trials involved critically ill patients [ 29 , 31 33 , 36 , 41 , 42 ], and ten involved non-critically ill patients [ 8 , 28 , 30 , 34 , 35 , 37 40 , 43 ]. The outcomes of the 28 clinical studies are summarized in Tables 3 and 4 .…”
Section: Resultsmentioning
confidence: 99%
“…Eight of the 11 RCTs compared therapeutic versus prophylactic doses of anticoagulants, and three trials compared moderate therapeutic versus prophylactic doses of anticoagulants. Seven of the 17 OBs trials involved critically ill patients [ 29 , 31 33 , 36 , 41 , 42 ], and ten involved non-critically ill patients [ 8 , 28 , 30 , 34 , 35 , 37 40 , 43 ]. The outcomes of the 28 clinical studies are summarized in Tables 3 and 4 .…”
Section: Resultsmentioning
confidence: 99%
“…A total of 36 articles were included in the pooled analysis ( Table 1 ). 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 The majority (28; 78%) consisted of retrospective cohort studies whereas three (8%) were RCTs and five (14%) were prospective cohort studies ( Table 1 ).…”
Section: Resultsmentioning
confidence: 99%
“… 33 Four observational studies yielded inconsistent results concerning the benefits of intermediate dose LMWH/UFH over low (prophylactic) dose LMWH/UFH. 20 , 31 , 32 , 34 Two RCTs (including the large RECOVERY trial, N = 14 892) 36 revealed no mortality benefit of antiplatelet therapy (including aspirin and P2Y12 inhibitors) as add‐on therapy among non–critically ill patients hospitalized for COVID‐19. 35 , 36 These trials also indicated evidence of harm with increased major bleeding events in patients on antiplatelet therapy.…”
Section: Treatment Recommendationsmentioning
confidence: 99%
“… 33 Four observational studies yielded inconsistent results concerning the benefits of intermediate dose LMWH/UFH over low (prophylactic) dose LMWH/UFH. 20 , 31 , 32 , 34 …”
Section: Treatment Recommendationsmentioning
confidence: 99%
See 1 more Smart Citation